In today’s recent session, 0.64 million shares of the Outlook Therapeutics Inc (NASDAQ:OTLK) have been traded, and its beta is 0.52. Most recently the company’s share price was $1.72, and it changed around $0.2 or 13.16% from the last close, which brings the market valuation of the company to $42.08M. OTLK at last check was trading at a discount to its 52-week high of $12.85, offering almost -647.09% off that amount. The share price’s 52-week low was $0.87, which indicates that the recent value has risen by an impressive 49.42% since then. We note from Outlook Therapeutics Inc’s average daily trading volume that its 10-day average is 8.4 million shares, with the 3-month average coming to 1.55 million.
Outlook Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.33. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended OTLK as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Outlook Therapeutics Inc is expected to report earnings per share of -0.9 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Instantly OTLK has been showing a green trend so far today with a performance of 13.16% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0500 on recent trading dayincreased the stock’s daily price by 16.1%. The company’s shares are currently down -78.17% year-to-date, but still down -15.27% over the last five days. On the other hand, Outlook Therapeutics Inc (NASDAQ:OTLK) is -74.21% down in the 30-day period. We can see from the shorts that 3.4 million shares have been sold at a short interest cover period of 11.43 day(s).
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Outlook Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -75.67 percent over the past six months and at a 20.00% annual growth rate that is well above the industry average of 17.10%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 52.49%.
OTLK Dividends
Outlook Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 35.58% of Outlook Therapeutics Inc shares, and 35.65% of them are in the hands of institutional investors. The stock currently has a share float of 55.34%. Outlook Therapeutics Inc stock is held by 95.0 institutions, with ROSALIND ADVISORS, INC. being the largest institutional investor. By 2024-06-30, it held 3.1534% of the shares, which is about 0.45 million shares worth $3.32 million.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024. The former held 442.51 shares worth $0.77 million, making up 1.87% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 373.43 shares worth around $0.65 million, which represents about 1.58% of the total shares outstanding.
